Connect Biopharmaceuticals is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. We have leveraged our expertise in the biology of T cell modulation to build a strong portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Our aim is to improve the lives of patients in China and around the world by creating novel medicines with better efficacy and fewer side effects. 

Our lead drug candidate is CBP-307, an internally-discovered, orally-active, next-generation S1P1 and S1P5 (a G-protein coupled receptor-GPCR) modulator for the treatment of a range of autoimmune disorders, including inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases.  We have completed two Phase 1 randomized, double-blind, placebo-controlled studies in 74 healthy volunteers to assess the tolerability, pharmacokinetics and pharmacodynamics of CBP-307. In these studies, CBP-307 exhibited excellent safety features and potent T cell modulation activity as well as optimal pharmacokinetics and pharmacodynamics profiles, demonstrating the best-in-class potential. CBP-307 is currently in Phase 2 studies for ulcerative colitis and Crohn's disease.

Our second drug candidate is CBP-201, an internally-discovered, highly potent antibody that targets IL-4Rα and blocks a critical pathway in allergic inflammation. It has the potential to treat a broad range of allergic inflammatory diseases such as atopic dermatitis, asthma, and nasal polyps, food allergy, eosinophilic esophagitis, and chronic obstructive pulmonary disease (COPD). CBP-201 is currently in a Phase 1 clinical study in healthy volunteers to determine its safety, tolerability, and pharmacokinetic and pharmacodynamic properties. A phase 1b clinical study in atopic dermatitis patients is expected to be initiated in Q1, 2019.

In addition, we are advancing three preclinical programs including CBP-174, CBP-233, and CBP-312 as treatments for various serious inflammatory conditions.

TEL/FAX: 0512-53577866

E-MAIL: swlu@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd. 苏ICP备17002143号

Technical support: Epower